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Abstract
Background: Paediatric tuberculosis (TB) represents a major public health concern worldwide. About 1 million
children aged less than 15 years develop TB each year, contributing to 3-25% of the total TB caseload. The aim of
this review is to evaluate national and international guidelines concerning tuberculosis in childhood and compare
them in terms of diagnosis and treatment strategies.
Methods: A literature search of the Pubmed database was performed from January 2000 to August 2013, using
the terms “tuberculosis” and “children”. The search was limited to guidelines and consensus conferences, human
species and full text availability, with no language restrictions.
Results: Twenty-seven national and international guidelines are identified. Several discrepancies on the diagnosis
workup of TB are underlined. The main points of disagreement are represented by the interpretation of tuberculin
skin test (TST) result and the recommendations on the use of TST and/or interferon-gamma release assay (IGRA) for
the diagnosis of TB infection. Otherwise, all guidelines are in agreement that a microbiological confirmation should
always be sought. Similarly, susceptibility drug testing and genotyping should be performed whenever it is
possible on the basis of resources availability. On the contrary, the use of nucleic acid amplification tests (NAATs)
for the M. tuberculosis detection is still controversial. A general consensus exists, otherwise, on TB treatment and
only minor discrepancies are evidenced, such as the recommendations on daily or intermittent treatment
regimens.
Conclusions: Despite advances in TB diagnostic tools have been reached during the last decade, a lack of
uniformity in their availability, indication and interpretation has relevant consequences for clinical practice. Further
studies need to be performed to clarify this issue and identify a reliable and reproducible diagnostic workup.
Moreover, future studies should analyze the drug metabolism and the efficacy of intermittent dosing regimes in
childhood, as well as new treatment regimens in order to improve the therapy compliance.
Background
Paediatric tuberculosis (TB) represents a major public
health concern worldwide. The World Health Organiza-
tion (WHO) reported that about 9 million people develop
TB each year, and of whom about 1 million (11%) occur in
children aged less than 15 years. Children contribute to
3–6% of the total TB caseload in developed countries and
to more than 25% of the burden of TB disease in develop-
ing countries [1]. Nonetheless, paediatric TB has been
relatively neglected for several years, mainly due to diffi-
culties in mycobacterium isolation in children. Novel
developments in diagnosis and treatment of paediatric TB
have been carried out and, more recently, the definition of
an adequate management of TB in childhood has become
one of the main aspects of the global TB control efforts
[1-4].
The aim of the present systematic review is to evalu-
ate and compare national and international guidelines
concerning diagnosis and treatment strategies in
paediatric TB.
Methods
A literature search of the Pubmed database was performed
from January 2000 to August 2013, using the terms
“tuberculosis” and “children” as key words. The search
was limited to type of article, guideline and consensus
conference, human species and full text availability, with
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no limits of language. The results were also restricted on
the basis of title and abstract. Therefore, 23 articles were
identified and of those 17 were considered relevant to the
goal of the research.
In order to verify the completeness of the Pubmed
database, a literature search of other databases (Web
of Science, Embase, Pascal and National Guideline
Clearinghouse) was also conducted, but the results
were virtually overlapping.
Additionally, the websites of relevant government
organizations and professional societies were reviewed
for documents of interest (WHO, Center for Disease
Control and Prevention - CDC, European Center for
Disease Control and Prevention - ECDC, National Insti-
tute for Health and Care Excellence - NICE, American
Academy of Pediatrics - AAP, International Union
Against Tuberculosis and Lung Disease - IUATLD,
American Thoracic Society - ATS, Canadian Thoracic
Society - CTS). All reference lists were examined in
order to identify pertinent publications, which were
added in the review.
All the results were closely evaluated and the papers
that were not pertinent or redundant were excluded. In
particular, our search was limited to guidelines developed
at national or international levels, excluding local or
regional recommendations, and overall 27 articles were
included in this review.
Results
The twenty-seven guidelines identified through the search
strategy are listed in table 1. Twelve guidelines regard
exclusively paediatric TB [1,5,9-12,23-26,28-30], whereas
15 guidelines analyze the management of TB in both
adults and children [6-8,13-22,27,31]. The majority of the
guidelines were focused on restricted fields concerning
paediatric TB, as diagnostic tools or treatment strategies,
whereas eight guidelines discuss extensively all aspects
related to the management of TB in childhood
[1,9,12,18,22,28,29,31].
Diagnostic tests for M. tuberculosis infection
The demonstration of M. tuberculosis infection is a rele-
vant part of the diagnosis of both TB disease and latent
TB infection (LTBI). LTBI is defined as M. tuberculosis
complex infection without clinical features or radiographic
findings of TB disease [1,12,21,29]. Children with LTBI are
at increased risk of developing active TB and becoming
infectious. Therefore the identification of children latently
infected with M. tuberculosis represents an important
issue of TB preventive strategies.
Tuberculin skin test (TST) and interferon-gamma
release assays (IGRAs) are immune-mediated methods
currently available for identifying M. tuberculosis infection
[1,6,9-12,14,16,19,21-23,28,29,31]. However, TST and
IGRA are not able to distinguish between latent TB infec-
tion and active disease, and a negative result does not
exclude the possibility of M. tuberculosis infection . There-
fore, according to the AAP [12], both TST and IGRAs
should not be considered a gold standard for the diagnosis
of LTBI.
The TST is based on the evidence that M. tuberculosis
infection promotes a delayed-type hypersensitivity reac-
tion to antigenic components isolated from tubercle
bacilli culture by protein precipitation (PPD), also known
as tuberculin. All guidelines recommend that TST should
be performed only in children who are at increased risk
of M. tuberculosis infection (i.e. contact with people with
contagious TB, HIV-infected children) or children with
suspected TB disease. The preferred method of PPD
administration is represented by Mantoux technique,
which consists of an intradermal injection of 5 tuberculin
units of PPD (0.1 ml) into the volar surface of the fore-
arm, using a 27-gauge needle. The test should be read
between 48 and 72 hours after the injection, measuring
the transverse diameter of the induration. However, the
interpretation of TST results is still controversial. The
majority of the guidelines [1,9-11,23,28,31] affirms that
TST should be considered positive if the diameter of the
induration is > 10 mm in any child and > 5 mm in high
risk children, including HIV-infected children and
severely malnourished children. Otherwise the American
guidelines [12,14] recommend three different cut-points.
Five millimetres should be considered positive in high-
risk children, including close contact with contagious
people with TB, suspect of TB disease (i.e. chest
radiograph suggestive of active or previous TB) and
immunodeficiency (i.e. HIV-infected children, children
receiving immunosuppressive therapy). In children at
increased risk of disseminated TB disease (i.e. children
younger than 4 years, children with other medical condi-
tions) and children with likelihood of being infected with
M. tuberculosis (i.e. children born in high prevalence
regions or children who travel to high prevalence regions)
the cut-off proposed is 10 mm. Eventually, TST > 15 mm
is positive in children aged 4 years or older without any
risk factors. All the guidelines agree that the TST result
should be interpreted as positive regardless of Bacille
Calmette-Guérin (BCG) vaccination, because there is no
way of distinguishing between a positive TST due to
M. tuberculosis infection and that caused by BCG
vaccination.
Over the last decade new diagnostic tests have been
developed for the detection of TB infection measuring,
ex-vivo, the interferon-gamma released by T-cells in
response to mycobacterial antigens (IGRAs) [32]. Quan-
tiFERON-TB Gold-In tube (Cellestis, Victoria, Australia)
and T-SPOT.TB (Immunotec, Oxford, United Kingdom)
have been approved by the United States Food and
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Table 1 National and international guidelines concerning paediatric tuberculosis.
Guideline Title [Reference] Guideline
Developer(s)
Countries or
Regions
Year Target
Population
Guideline
Fields
Guidance for national tuberculosis programmes on the management of tuberculosis
in children [1]
WHO International 2006 Children Diagnosis
Treatment
Rapid advice. Treatment of tuberculosis in children [5] WHO International 2010 Children Treatment
Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-
income countries: policy statement [6]
WHO International 2011 Adults
Children
Diagnosis
Policy statement: automated real-time nucleic acid amplification technology for
rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert
MTB/RIF system [7]
WHO International 2011 Adults
Children
Diagnosis
Guidelines for the programmatic management of drug-resistant tuberculosis [8] WHO International 2011 Adults
Children
Treatment
Desk-guide for diagnosis and management of TB in children [9] IUATLD International 2010 Children Diagnosis
Treatment
Evaluation of Tuberculosis Diagnostics in Children [10,11] Expert Panel International 2012 Children Diagnosis
Tuberculosis (in: Red Book 2012) [12] AAP U.S. 2012 Children Diagnosis
Treatment
Treatment of Tuberculosis [13] ATS
CDC
IDSA
U.S. 2003 Adults
Children
Treatment
Diagnostic Standards and Classification of Tuberculosis in Adults and Children [14] ATS
CDC
IDSA
U.S. 2000 Adults
Children
Diagnosis
Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis
of Tuberculosis [15]
CDC U.S. 2009 Adults
Children
Diagnosis
Updated Guidelines for Using Interferon Gamma Release Assays to Detect
Mycobacterium tuberculosis Infection [16]
CDC U.S. 2010 Adults
Children
Diagnosis
Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct
Observation to Treat Latent Mycobacterium tuberculosis Infection [17]
CDC U.S. 2011 Adults
Children
Treatment
European Union Standards for Tuberculosis Care [18] ECDC
ERS
Europe 2012 Adults
Children
Diagnosis
Treatment
Use of interferon-gamma release assays in support of TB diagnosis [19] ECDC Europe 2011 Adults
Children
Diagnosis
Management of contacts of MDR TB and XDR TB patients [20] ECDC Europe 2012 Adults
Children
Diagnosis
Treatment
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A
TBNET consensus statement [21]
TBNET Europe 2009 Adults
Children
Diagnosis
Clinical diagnosis and management of tuberculosis, and measures for its prevention
and control [22]
NICE U.K. 2011 Adults
Children
Diagnosis
Treatment
Diagnosis of tuberculosis in pediatrics. Consensus document of the Spanish Society
of Pediatric Infectology (SEIP) and the Spanish Society of Pediatric Pneumology
(SENP) [23]
SEIP
SENP
Spain 2010 Children Diagnosis
Consensus document for the treatment of pulmonar tuberculosis in children [24] SEIP Spain 2007 Children Treatment
Recommendations of the Spanish Society for Pediatric Infectious Diseases (SEIP) on
the management of drug-resistant tuberculosis [25]
SEIP Spain 2009 Children Treatment
Consensus document on treatment of tuberculosis exposure and latent tuberculosis
infection in children [26]
SEIP Spain 2006 Children Treatment
Recommendations for Therapy, Chemoprevention and Chemoprophylaxis of
Tuberculosis in Adults and Children [27]
DZK
DGP
Germany 2012 Adult
Children
Treatment
Childhood tuberculosis guidelines of the Southern African Society for Paediatric
Infectious Diseases [28]
SASPID South Africa 2009 Children Diagnosis
Treatment
Consensus Statement on Childhood Tuberculosis [29] IAP India 2010 Children Diagnosis
Treatment
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Drug Administration [19] and licensed for commercial
distribution in Europe [16] and several other countries
[28,29,31].
All the recent guidelines are in agreement that IGRAs
represent a relevant diagnostic tools for the identification
of M. tuberculosis infection, except for one [9] which do
not discuss the role of IGRAs in the diagnosis of TB
infection. The CDC, the ECDC and the WHO have pub-
lished specific recommendations focusing on the use of
IGRAs in TB and LTBI diagnosis [6,16,19]. They analyze
the sensitivity and specificity of the test, the costs and the
role of IGRAs in the diagnosis of TB infection both in
adults and children. Whereas the guidelines developed in
high-income settings discuss extensively the use of
IGRAs [21-23,31], those from middle or low-income
countries only mention IGRAs [28,29].
All guidelines underline that few data concerning the
use of IGRAs in childhood are available, but the IGRAs
seem to perform well in children aged 5 years or older.
The sensitivity of IGRAs for detecting TB infection in
childhood is generally similar to TST, according also to
recent meta-analysis [32-34]. The IGRAs specificity seems
to be higher than TST, because the antigens used are
absent in most pathogenic non-tuberculous mycobacteria,
as well as in BCG strains. This characteristic explains the
IGRAs advantage over TST in identifying a natural M.
tuberculosis infection in settings with high non-tubercu-
lous mycobacteria exposure and high BCG vaccination
coverage [21,35]. Moreover boosting does not occur when
the test is repeated, being particularly useful in BCG-
vaccinated children. Anyway the IGRA tests have a
reduced accuracy for the detection of M. tuberculosis
infection in high-burden TB settings compared with low-
burden TB settings [33,35]. Indeed IGRAs are unsuitable
for resource-limited settings, being expensive and requir-
ing sophisticated laboratory support and trained personal
for accurate performance. According to that, the WHO
[6] strongly recommends that IGRAs should not replace
the TST for the detection of TB infection in children in
low or middle-income countries, regardless of HIV status.
On the contrary, the NICE guidelines [22] encourage the
use of IGRAs and suggest considering those for all chil-
dren aged 5 years or older whose TST shows positive
results. Differently, European [19], Spanish [23], Canadian
[31] and American [12,16] guidelines affirm that the selec-
tion of the most suitable test or combination of tests
should be based on clinical data, as BCG status, history of
contact with active TB or other risk factors for infection
or progression of the disease (table 2).
Diagnostic tools for TB disease
All guidelines [1,9-12,14,18,22,23,28,29,31] agree that the
isolation of M. tuberculosis complex from different spe-
cimens as sputum (natural or induced), gastric aspirates,
bronchial washings, pleural fluid, cerebrospinal fluid, urine
or biopsy tissue is the gold standard for the diagnosis of
TB. Older children and adolescents frequently can
produce sputum spontaneously or by induction with aero-
solized hypertonic saline. Otherwise early-morning gastric
aspirate, collected on three separate days, represents an
option for young children and any child in whom sputum
cannot be obtained. All guidelines underline that a
microbiological confirmation should always be sought
using all the resources available, although is well known
that children are generally paucibacillary.
The first bacteriological evidence of the presence of
mycobacteria in a clinical specimen is the detection of
acid fast bacilli (AFB) in stained smears examined micro-
scopically. This test gives an estimation of the numbers of
bacilli excreted and therefore of the patient’s infectious-
ness. However, the results of AFB smears of gastric
aspirates are often negative and also the presence of non-
tubercolous mycobacteria, can cause false-positive results
[12,31]. For these reasons all clinical specimens should be
inoculated into culture media. Despite culture is the gold
standard for laboratory confirmation of TB disease,
M. tuberculosis is isolated from less than 50% of children
and 75% of infants with pulmonary tuberculosis [12,31,36].
In low-income settings, where the facilities and
resources are limited, bacteriological confirmation should
Table 1 National and international guidelines concerning paediatric tuberculosis. (Continued)
Management of tuberculosis in children [30] ASID
APRG
Australasia 2000 Children Treatment
Canadian Tuberculosis Standards 7th Edition [31] PHAC
CTS
CLA
Canada 2013 Adult
Children
Diagnosis
Treatment
Note. WHO: World Health Organization; IUATLD: International Union Against Tuberculosis and Lung Disease; AAP: American Academy of Pediatrics; ATS: American
Thoracic Society; CDC: Center for Control Disease and Prevention; IDSA: Infectious Diseases Society of America; ECDC: European Center for Disease Control and
Prevention; ERS: European Respiratory Society; NICE: National Institute for Health and Care Excellence; SEIP: Spanish Society for Paediatric Infectious Diseases;
SENP: Spanish Society for Paediatric Respiratory Disease; DZK: German Central Committee against Tuberculosis; DGP: German Respiratory Society; SASPID:
Southern African Society for Paediatric Infectious Diseases; IAP: Indian Academy of Pediatrics; ASID: Australasian Society for Infectious Diseases (Subgroup of
Paediatric Infectious Disease); APRG: Australasian Paediatric Respiratory Group; PHAC: Public Health Agency of Canada; CTS: Canadian Thoracic Society; CLA:
Canadian Lung Association.
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be prioritized in children who have HIV infection, compli-
cated or severe disease or suspected drug-resistant TB
[1,28]. Moreover, the growth of the mycobacteria in cul-
ture is required not only for confirming the diagnosis and
determining the mycobacteria species, but also for geno-
typing and drug susceptibility testing, according to all
guidelines. Although all guidelines underline the impor-
tance of genotyping and drug susceptibility testing, only
American and Spanish guidelines describe the methods
used [14,23].
A relevant improvement in the direct identification of
M. tuberculosis resulted from the introduction of nucleic
acid amplification test (NAAT). The CDC [15] and the
WHO [7] have recently published an updated guidelines
for the use of NAAT in the diagnosis of TB in both chil-
dren and adults, although some guidelines only explain
briefly their potential implications [12,18,22,23,28,29,31],
and other do not consider this topic [9-11]. The NAATs
are rapid and accurate methods. They can provide the
results within 24-48 hours, one or more weeks earlier than
culture. Global sensitivity is greater than 95% in AFB-
microscopy positive respiratory specimens and ranges
between 50-80% in AFB-smear negative specimens [15].
Currently several assays are available, including line probe
assays (LPAs) and NAATs using polymerase chain
reaction (PCR). Real-time PCR is becoming increasingly
available and several guidelines purpose its use for
M. tuberculosis detection in respiratory specimens
[7,12-15,18,22,23,28,31]. The CDC [15] recommends the
use of NAAT in any patient with signs and symptoms of
pulmonary TB, for whom a diagnosis has not yet been
established or for whom the test result would change the
case management. The NICE guideline [22], on the
contrary, limits NAAT use only to sputum smear positive
persons for whom the rapid confirmation of TB diagnosis
would change their care. Other guidelines [23,28,31]
underline the useful of NAAT, but they do not provide
specific indications. However, all guidelines agree that
Table 2 Recommendations for the use of Tuberculin Skill Test (TST) and Interferon-gamma Release Assay (IGRA) in
children
TST alone IGRA alone both TST and IGRA
WHO [6] • Any child, irrespective of HIV status, in low and
middle-income countries
NICE [22] • Children younger than 5 years • BCG vaccinated children (> 5 years of
age)
• Children > 5 years of age, in an
outbreak situation
• Children > 5 years of age whose TST
is positive
American
[12,16]
• Children younger than 5 years
• Before initiation of immunosuppressive therapy
• BCG vaccinated children (> 5 years of
age)
• Children > 5 years of age who are
unlikely to return for TST reading
• Before starting immunosuppressive
therapy
• The initial and repeat IGRA are
indeterminate
• The initial test (TST or IGRA) is
negative and:
- clinical suspicion for TB disease is
moderate to high
- risk of progression and poor outcome
is high
• The initial TST is positive and:
- Children > 5 years of age who have
received BCG vaccine
- Non-tuberculous mycobacterial
disease is suspected
- Additional evidence are needed to
increase compliance
European
[19]
• Children younger than 5 years
• Children > 5 years who are:
- not HIV-infected
- not BCG vaccinated
• BCG vaccinated children (> 5 years of
age)
• HIV-infected children
• Before starting immunosuppressive
therapy (anti-TNFalfa inhibitor therapy)
Spanish
[23]
• Any child • The initial TST is negative and:
- Immunocompromised children
- High risk of infection, of progression
to disease and of a poor outcome
• The initial TST is positive and:
- BCG vaccinated children
- Risk factors are negative
Canadian
[31]
• Whenever it is planned to repeat the test later
to assess risk of new infection (i.e. conversions)
• People who have received BCG
vaccination
• People from groups that historically
have poor rates of return for TST reading.
• High risk of infection, of progression
to disease and of a poor outcome
• The initial and repeat IGRA are
indeterminate
Note. WHO: World Health Organization; BCG: Bacille Calmette-Guèrin
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NAATs do not replace AFB smear and culture, which
should be always performed. Moreover the NAATs should
not be used for treatment monitoring as they persist
positive for long periods after therapy, being unable to
distinguish live from dead bacilli.
However, evidence concerning NAATs accuracy for non-
respiratory specimens are limited. Further research is
needed before NAATs can be recommended for the diagno-
sis of TB in children who cannot produce sputum [12,15].
The NAATs are also able to detect drug resistance. If
the AFB-smear is negative, as it frequently occurs in
children, the NAAT of choice is the Xpert-MTB/RIF
(Cepheid, Sunnyvale, California, USA) which is a real-time
PCR assay detecting the 81-bp-core region of the RNA-
polymerase b-subunit gene. This region, which is closed to
M. tuberculosis specific DNA sequences, accounts for
more than 95% of rifampicin (RIF) resistance. Therefore
the Xpert-MTB/RIF can be used for the detection of
RIF-resistance [37,38]. Additionally, given that rifampicin
resistance is usually accompanied by isoniazid resistance,
it can be used also as a rapid marker of multi-drug resis-
tant (MDR) TB. According to these findings, the WHO
[7,8] recommends the Xpert-MTB/RIF as the initial diag-
nostic test in children and adolescents suspected of having
multidrug-resistant (MDR)-TB or HIV-associated TB. The
WHO also suggests to consider it as a follow-on test to
microscopy in settings where MDR-TB or HIV are of les-
ser concern, especially in further testing of smear-negative
specimens. The ECDC guidelines [18] confirm the WHO
recommendations.
Among radiological tools, all guidelines [1,9-12,18,
22,23,28,29,31] are in agreement that chest radiography is
an important part of the diagnostic workup of TB and
should be performed in any child with suspected TB.
Chest radiographic features vary widely, showing normal
findings as well as lymphadenopathy, atelectasis, cavitary
lesions, miliary disease and pleural effusion. There are no
pathognomonic radiological sings of TB, but some radiolo-
gical lesions strongly suggest TB, as miliary disease, hilar
and paratracheal lymphadenopathy or cavitary lesions.
A general consensus exists also concerning the use of
chest CT only for complicated cases, considering the
high level of radiation exposure and the high costs
related to its use.
The CT, as well as magnetic resonance, may also be very
helpful in the evaluation of TB meningitis, osteoarticular
disease, intra or extra-thoracic lymphadenopathy and
pericardial TB.
Treatment for TB disease
The major goals of anti-TB treatment are to cure the
patient by eliminating most of the bacilli, prevent the
development of drug resistance by using a drug combina-
tion regimen, prevent TB relapse by eliminating the quies-
cent bacilli and, finally, decrease the TB transmission to
others.
The poor adherence to the anti-TB therapy represents
the main contributory factor to treatment failure and
emergence of TB drug-resistance. In order to improve the
compliance to the treatment, all guidelines [1,5,9,12,
13,18,22,24,25,27-31] emphasize the widespread use of the
directly observed therapy (DOT), a patient-centred strat-
egy in which patients are observed to ingest each dose of
anti-TB drugs.
All guidelines are also in agreement that TB treat-
ment should include an initial intensive phase, when
three to four drugs are used in order to kill the major-
ity of bacilli and prevent the emergence of drug resis-
tance, and a continuation phase, when fewer drugs are
given in order to eradicate quiescent bacilli. The first-
line anti-TB drugs, their dosages and adverse events
are summarized in table 3. The guidelines considered
in the present review recommend the same standard
treatment regimen for pulmonary TB (table 4).
Children living in settings were HIV prevalence is high
or isoniazid (INH)-resistance is high, or both, should
be treated with a four drugs regimen (INH, RIF, pyrazi-
namide-PZA and ethambutol-EMB) for 2 months,
followed by a two drugs regimen (INH, RIF) for 4
months. However, if the risk of drug-resistance and the
HIV prevalence are low, EMB can be omitted, consid-
ering that it can cause retrobulbar neuritis and could
be difficultly monitoring in children. Despite two
recent systematic reviews [39,40] show that an
Table 3 First-line drugs used for treatment of tuberculosis in childhood [1,9,12,13,24,27-31]
Daily dosage
(maximum dosage)
Twice-thrice weekly dosage
(maximum dosage)
Adverse Reactions
Isoniazid
(INH)
10-15 mg/kg
(300 mg)
20-30 mg/kg
(900 mg)
Hepatotoxic effects , such as mild hepatic enzyme elevation and hepatitis,
gastritis, peripheral neuropathy, hypersensitivity
Rifampicin
(RIF)
10-20 mg/kg
(600 mg)
10-20 mg/kg
(600 mg)
Orange discoloration of secretions and urine, vomiting, hepatitis, influenza-
like reaction, thrombocytopenia
Pyrazinemide
(PZA)
30-40 mg/kg
(2 g)
50 mg/kg
(2 g)
Hepatotoxic effects, hyperuricemia, arthralgia, gastrointestinal tract
disturbances
Ethambutol
(EMB)
15-25 mg/kg
(2,5 g)
50 mg/kg
(2,5 g)
Optic neuritis with decreased red-green colour discrimination and visual
acuity, gastrointestinal disturbances, hypersensitivity
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intermittent short course of therapy is less likely to
cure tuberculosis in childhood compare to daily ther-
apy, several guidelines [1,5,9,12,13,22,24,27,30,31] pur-
pose both daily and intermittent (twice or thrice
weekly) dosing regimens, and major discrepancies are
evidenced. The AAP [12], the ATS along with the CDC
[13], as well as the APRG along with ASID [30] recom-
mend a daily or twice-weekly regimen in both intensive
and continuation phases. The NICE [22], otherwise,
excludes the use of twice-weekly regimen for the treat-
ment of active TB, suggesting a thrice-weekly intermit-
tent regimens only for patients receiving DOT. The
WHO [1], the IUATLD [9] and the CTS [31] limit a
thrice-weekly regimen to children known to be HIV
uninfected and living in settings with well established
DOT, and they allow an intermittent regimen only dur-
ing the continuation phase. Finally Spanish guidelines
[24] agree that children who are known to be reliable
with DOT may be considered for both twice and
thrice-weekly regimens.
A general consensus exists concerning treatment
regimes for extra-pulmonary TB (table 4): except for
meningitis and osteoarticular TB, the standard recom-
mended regimen (INH + RIF + PZA + EMB for 2 months,
followed by INH + RIF for 4 months) should be started.
Otherwise, the guidelines strongly recommend 12 months
of therapy for meningeal TB [1,5,9,12,13,22,27,30,31] and
osteoarticular TB [1,5,9,22,27,30,31].
Among drug-resistance TB, only few guidelines
[1,8,12,25,30,31] provide specific recommendations, prob-
ably due to the lack of evidence concerning this issue in
childhood. Recommended regimens [8,12,25,30,31] for
INH-monoresistance and RIF-monoresistance TB are
listed in table 4. Despite the evidence concerning safety
and efficacy in TB treatment of fluoroquinolones in chil-
dren are few, all guidelines recommend their introduction
in the treatment of monodrug-resistance TB, considering
the indirect evidence from cystic fibrosis and osteomyelitis
treatment in children.
The AAP [12] define the MDR as a TB infection or
disease caused by a strain of M. tuberculosis complex that
is resistant to at least INH and RIF. For MDR-TB cases, all
guidelines [1,8,18,12,25,30,31] are in agreement that the
treatment should be based on the drug susceptibility
pattern of the M. tuberculosis isolated from child speci-
mens or, more frequently, from the source case specimens.
All guidelines also affirm that treatment regimen should
include at least four anti-TB drugs to which the organism
isolated is susceptible [1,8,18,12,25,31], except for Austra-
lasian one that recommends the use of at least two drugs
Table 4 Recommendations for treatment of TB in childhood [1,8,9,12,13,17,18,21,22,24,27-31]
Intensive phase
(duration)
Continuation phase
(duration)
TB disease (except meningitis and osteoarticular TB) in HIV-uninfected children with
low risk of INH-resistance
INH + RIF + PZA (2
months)
INH + RIF (4 months)
TB disease (except meningitis and osteoarticular TB) in HIV-infected children and/or
children with high risk of INH-resistance
INH + RIF + PZA + EMB
(2 months)
INH + RIF (4 months)
Meningitis and osteoarticular TB INH + RIF + PZA + EMB
(2 months)
INH + RIF (10 months)
INH-monoresistance TB RIF + PZA + EMB (2
months)§
RIF + PZA + EMB (4-7
months)§
RIF + PZA + EMB (2
months)#
RIF + EMB (10 months) #
RIF + PZA + EMB + FQN
(2 months) #
RIF + EMB + FQN (4-7
months) #
RIF-monoresistance TB INH+ PZA + EMB + FQN
(2 months) §
INH + EMB + FQN (10-
16 months) §
INH + PZA + EMB (2
months) #
INH + EMB (16 months)
#
MDR-resistance TB Treatment regimens should be based on the drug
susceptibility pattern of the M. tuberculosis isolated
from child specimens or, more frequently, from the
source case specimens.
LTBI INH (6-9 months) §
INH + RIF (3 months) #
INH + RPT (weekly for 12 weeks) #
INH-monoresistance LTBI RIF (4-6 months)
Note: § recommended regimen; # alternative regimen; TB: Tuberculosis; INH: Isoniazid; RIF: Rifampicin; PZA: Pyrazinamide; EMB: Ethambutol; FQN:
Fluoroquinolones; MDR: Multi- Drug Resistance; RPT: Rifabutin.
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certain to be effective [30]. Additionally treatment dura-
tion should be prolonged and ranges from 12 to 24
months in the different guidelines [1,8,18,12,25,30,31].
Second-line drugs used in paediatric TB are listed in
table 5.
Treatment for LTBI
After exposure to an active case, children are more likely
to develop tuberculosis than adults, hence contact screen-
ing and chemoprophylaxis are particularly important.
Several guidelines discuss LTBI and its treatment
[1,12,13,17,18,21,26-31] and all of those are in agreement
that any child who has an history of TB exposure, positiv-
ity of TST and/or IGRA, but not evidence of active tuber-
culosis, should start the treatment for LTBI (table 4).
Isoniazid represents the preferred drug for children with
LTBI, unless INH-resistance is suspected, and the efficacy
approaches about 100% if the adherence to therapy is ade-
quate [12]. All guidelines [1,12,13,17,18,21,26-31] suggest
using isoniazid alone for LTBI treatment in childhood
although minor differences concern the treatment dura-
tion, which ranges from 6 months [1,22,26,28-30] to 9
months [12,13,17,21,27,31]. Additionally the NICE [22]
and the Southern African [28] guidelines purpose 3
months of INH and RIF as alternative therapy regimen.
Recently the CDC has published recommendations for the
use of a new combination regimen of rifapentin (RPT) and
INH to be administered weekly for 12 weeks as DOT [17].
Although the evidence on tolerability and efficacy of this
combination in childhood is lacking, it can be considered
in selected cases, if the compliance to treatment is low and
the hazard of TB is high.
Rifampicin alone for 4-6 months is recommended for
the treatment of LTBI if a resistance to INH is strongly
suspected or demonstrated [1,12,13,21,26,27,30,31].
However, on the basis of the currently available evi-
dences, second-line drugs are not recommended for the
chemoprophylaxis in MDR-TB contacts.
Conclusions
The present systematic review has identified 27 national
and international guidelines concerning the management
of paediatric tuberculosis [1,5-31].
There are several discrepancies on the diagnosis workup
of TB. Major differences concern the TST interpretation.
Most of the guidelines [1,9-11,23,28,31] establish a cut-
point of 10 mm for any child and 5 mm for high risk
children, although the American guidelines [12,14]
increase the cut-point to 15 mm for children without any
risk factors and to 10 mm for children with minor risk
factors, maintaining the diameter of 5 mm only for high
risk population. Considering that TST sensitivity and spe-
cificity are influenced by the cut-off used [21], differences
among guidelines are not merely academic but have
important consequences for clinical practice. Recommen-
dations also differ substantially regarding the use of TST
and IGRA for the diagnosis of TB infection. The guide-
lines from high-income countries [12,16,22,23,19,31]
widely promotes the IGRA use, whereas the WHO [6]
strongly recommends that IGRAs should not replace the
TST for the detection of TB infection in children in low or
middle-income countries. These findings could be
explained considering that IGRA has a reduced accuracy
in high-burden TB settings compared with low-burden TB
Table 5 Second-line drugs used for TB treatment in children [8,12,13,25,27,30,31]
Daily dosage (maximum dosage) Adverse Reactions
Streptomycin 20-40 mg/kg
(1 g)
Auditory, vestibular and renal toxicity, rash
Amikacin
Kanamycin
Capreomycin
15-30 mg/kg
(1 g)
Auditory, vestibular and renal toxicity
Ethionamide 15-20 mg/kg/die, given in 2-3 divided
doses
(1 g)
Hepatotoxic effects, gastrointestinal tract disturbances, neurotoxicity, hypersensitivity
and hypothyroid
Para-amino salicylic
acid
200-300 mg/kg/die, given in 2-4
divided doses
(10 g)
Hepatotoxic effects, gastrointestinal tract disturbances, hypersensitivity
Cycloserine 10-20 mg/kg, given in 2-divided doses
(1 g)
Psychosis, personality changes, seizure, rash
Moxifloxacin 10 mg/kg
(400 mg)
Theoretical effect on growing cartilage, gastrointestinal tract disturbances, rash,
headache, restlessness
Levofloxacin 10 mg/kg
(1 g)
Linezolid 10 mg/kg
(1,2 g)
gastrointestinal tract disturbances, peripheral neuropathy, thrombocytopenia
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settings [33,35], is expensive and requires sophisticated
laboratory support and trained personal [6,16,21].
A general consensus exists, on the contrary, on the
microbiological confirmation of TB diagnosis, despite in
low-income settings the mycobacterial culture is not per-
formed routinely and is limited to HIV-infected children
or severe disease. Although all guidelines underline the
importance of susceptibility drug testing and genotyping,
the guidelines from low-income countries do not strongly
recommend these tests routinely to all patients, probably
because of costs and lack of facilities. Finally the use of
NAATs for the direct detection of M. tuberculosis is still
controversial. Whereas the CDC [15] and the WHO [7]
have recently published an updated guidelines focusing on
the use of NAATs, the majority of guidelines
[12,18,23,28,29,31] do not provide specific recommenda-
tions on their use. Moreover, evidence concerning NAATs
accuracy for non-respiratory specimens are limited and
further research is needed before NAATs can be recom-
mended for the diagnosis of TB in children who cannot
produce sputum [12,15].
Despite advances in TB diagnostic tool have been
reached over the last decade, a lack of uniformity in their
availability, indication and interpretation has relevant
consequences for clinical practice. Further research is
needed to identify a reliable and reproducible diagnostic
workup not only to improve individual case management,
but also to provide a valid basis for epidemiological data
analysis, drug efficacy evaluation and improving clinical
trials.
The recommendations on TB treatment are otherwise
homogeneous and only minor discrepancies are evidenced
in the present review. The main point of disagreement is
represented by the daily and intermittent (twice or thrice
weekly) regimens recommended, which vary widely
between different guidelines. The lack of evidence among
the drugs metabolism and the efficacy of intermittent treat-
ment regimes in childhood is probably the main reason of
this finding. Further studies need to be performed in order
to clarify this issue. Finally, the poor adherence to the ther-
apy, which is often too long, represents a relevant concern,
especially in low-income settings where DOT is not always
guarantied. The combination regimen of RPT and INH,
recently proposed by the CDC for LTBI, could be a valid
alternative in these patients. Data on efficacy and safety of
this combination are needed before address new recom-
mendations. Moreover, new treatment regimens, indicated
also for active TB, should be analyzed in future studies in
order to improve the treatment compliance.
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